Loading…
CIK 0001839948 • 6 13F filings • May 14, 2025 – Aug 14, 2026
Import this data to Google Sheets with:
=jivedata("tcg-crossover-management-llc","13f")Uses this filer's slug. Install the Jive Data add-on first; the second argument is "13f".
Past 5 quarters
| % of Portfolio | |||||
|---|---|---|---|---|---|
| ABIVAX SA AMERICAN DEPOSITARY SHARES | ADRS | $959.0M | 31.7%Prev: 29.7% | 7,111,596 SH | Increased |
| ADC THERAPEUTICS SA | COMM | $40.2M | 1.3%Prev: 0.3% | 11,390,175 SH | Increased+10,000,000 SH |
| AGIOS PHARMACEUTICALS INC | COMM | $32.2M | 1.1%Prev: 2.8% | 1,181,841 SH | Decreased-248,200 SH |
| ALECTOR INC | COMM | $15.6M | 0.5% | 10,000,000 SH | New |
| AMYLYX PHARMACEUTICALS INC | COMM | $75.4M | 2.5%Prev: 4.2% | 6,243,812 SH | Decreased |
| ARVINAS HOLDING CO LLC | COMM | $31.6M | 1.0%Prev: 0.7% | 2,666,216 SH | Increased+1,048,851 SH |
| Athira Pharma, Inc. | COMM | $3.3M | 0.1% | 464,398 SH | New |
| AVALO THERAPEUTICS INC | COMM | $8.8M | 0.3%Prev: 0.3% | 483,000 SH | Increased |
| BIOHAVEN LTD | COMM | $52.3M | 1.7% | 4,631,317 SH | New |
| CENTESSA PHARMACEUTICALS PLC | ADRS | $107.2M | 3.5%Prev: 3.7% | 4,286,480 SH | Increased+1,150,000 SH |
| CG ONCOLOGY INC | COMM | $152.4M | 5.0%Prev: 7.3% | 3,670,206 SH | Increased |
| COGENT BIOSCIENCES INC | COMM | $208.4M | 6.9%Prev: 4.8% | 5,868,162 SH | Increased-930,000 SH |
| DIANTHUS THERAPEUTICS INC | COMM | $69.1M | 2.3%Prev: 3.2% | 1,676,624 SH | Increased |
| DYNE THERAPEUTICS INC | COMM | $90.3M | 3.0%Prev: 2.9% | 4,615,144 SH | Increased |
| ENTRADA THERAPEUTICS INC | COMM | $21.5M | 0.7%Prev: 0.2% | 2,088,392 SH | Increased+1,503,437 SH |
| EYEPOINT PHARMACEUTICALS INC | COMM | $65.3M | 2.2%Prev: 2.5% | 3,572,335 SH | Increased |
| FULCRUM THERAPEUTICS INC | COMM | $59.4M | 2.0%Prev: 2.4% | 5,250,000 SH | Increased |
| IMMUNOVANT INC | COMM | $42.2M | 1.4% | 1,660,933 SH | New |
| JANUX THERAPEUTICS INC | COMM | $24.7M | 0.8% | 1,789,617 SH | New |
| KODIAK SCIENCES INC | COMM | $40.4M | 1.3%Prev: 0.9% | 1,445,538 SH | Increased+300,000 SH |
| KORRO BIO INC | COMM | $3.3M | 0.1%Prev: 1.0% | 416,301 SH | Decreased |
| LB PHARMACEUTICALS INC | COMM | $38.8M | 1.3%Prev: 1.4% | 1,745,015 SH | Increased-1 SH |
| LIQUIDIA TECHNOLOGIES INC | COMM | $59.0M | 2.0%Prev: 1.9% | 1,710,084 SH | Increased |
| MAZE THERAPEUTICS INC | COMM | $7.2M | 0.2% | 173,816 SH | New |
| MBX BIOSCIENCES INC | COMM | $20.5M | 0.7%Prev: 0.6% | 650,000 SH | Increased |
| MIRUM PHARMACEUTICALS INC | COMM | $4.9M | 0.2% | 62,049 SH | New |
| MONOPAR THERAPEUTICS INC | COMM | $9.3M | 0.3%Prev: 0.6% | 141,915 SH | Decreased-11,085 SH |
| MONTE ROSA THERAPEUTICS INC | COMM | $72.5M | 2.4% | 4,622,151 SH | New |
| OCULAR THERAPEUTIX INC | COMM | $69.7M | 2.3%Prev: 3.5% | 5,740,231 SH | Decreased-377,001 SH |
| RAPT THERAPEUTICS INC | COMM | $87.5M | 2.9%Prev: 2.1% | 2,582,408 SH | Increased+946,133 SH |
| RELAY THERAPEUTICS INC | COMM | $27.2M | 0.9%Prev: 0.5% | 3,220,186 SH | Increased+1,409,835 SH |
| REVOLUTION MEDICINES INC | COMM | $34.8M | 1.2%Prev: 1.0% | 436,473 SH | Increased |
| SAVARA INC | COMM | $74.5M | 2.5%Prev: 2.2% | 12,362,205 SH | Increased |
| SILENCE THERAPEUTICS PLC | ADRS | $18.4M | 0.6%Prev: 0.8% | 3,033,560 SH | Increased |
| SPYRE THERAPEUTICS INC | COMM | $62.3M | 2.1%Prev: 0.9% | 1,900,582 SH | Increased+800,000 SH |
| STRUCTURE THERAPEUTICS INC | ADRS | $64.0M | 2.1%Prev: 1.5% | 920,857 SH | Increased-142,143 SH |
| TANGO THERAPEUTICS INC | COMM | $113.1M | 3.7%Prev: 3.5% | 12,762,094 SH | Increased+4,225,898 SH |
| TYRA BIOSCIENCES INC | COMM | $76.2M | 2.5%Prev: 2.0% | 2,898,103 SH | Increased |
| UPSTREAM BIO INC | COMM | $20.2M | 0.7%Prev: 2.0% | 743,886 SH | Decreased-1,373,217 SH |
| UROGEN PHARMA LTD | COMM | $16.8M | 0.6%Prev: 0.7% | 717,347 SH | Increased |
| VENTYX BIOSCIENCES INC | COMM | $2.9M | 0.1%Prev: 0.0% | 316,195 SH | Increased |
| VISTAGEN THERAPEUTICS INC | COMM | $1.8M | 0.1%Prev: 0.5% | 2,676,580 SH | Decreased |
| XENCOR INC | COMM | $37.5M | 1.2%Prev: 1.4% | 2,452,138 SH | Increased |
| 13F-HR |
| 0001214659-26-010290 |
| $4.16B |
| View |
| Aug 14, 2025 | Q2 2025 | 13F-HR | 0001214659-25-012291 | $875.5M | View |
| May 15, 2026 | Q1 2026 | 13F-HR | 0001214659-26-006367 | $3.50B | View |
| May 14, 2025 | Q1 2025 | 13F-HR | 0001214659-25-007553 | $733.1M | View |